PCM
KPTI icon

Piermont Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Piermont Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,405
Closed -$480K – 262
2016
Q4 		$480K Sell
3,405
-67
-2% -$9.06K 0.11% 230
2016
Q3 		$507K Buy
+3,472
New +$417K 0.12% 234

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Piermont Capital Management's KPTI Position: Q1 2017 in Review

Piermont Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2017, closing a stake of 3,405 shares — an estimated $480K sold.

Piermont Capital Management first reported a position in KPTI in Q3 2016 and held it in 2 quarters. The position peaked at $507K in Q3 2016. 80 funds tracked by Wall St. Rank hold KPTI as of Q1 2017.

  • Piermont Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Piermont Capital Management sold 3,405 Karyopharm Therapeutics shares in Q1 2017, an estimated $480K.
  • Piermont Capital Management first reported a position in Karyopharm Therapeutics in Q3 2016 and held it in 2 quarters.
  • Piermont Capital Management's Karyopharm Therapeutics position peaked at $507K in Q3 2016.
  • 80 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2017.

Based on Piermont Capital Management's 13F filing for Q1 2017, filed 11 May 2017.